JP2008522617A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008522617A5 JP2008522617A5 JP2007545564A JP2007545564A JP2008522617A5 JP 2008522617 A5 JP2008522617 A5 JP 2008522617A5 JP 2007545564 A JP2007545564 A JP 2007545564A JP 2007545564 A JP2007545564 A JP 2007545564A JP 2008522617 A5 JP2008522617 A5 JP 2008522617A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- mutein
- substituted
- ala134cys
- leu118cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001413 amino acids Chemical group 0.000 claims description 22
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 16
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 102220537623 Aurora kinase C_N121A_mutation Human genes 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000056713 human FGF21 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102200079623 rs267606820 Human genes 0.000 claims 1
- 102220401008 rs397514353 Human genes 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000006240 deamidation Effects 0.000 description 6
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 5
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63588204P | 2004-12-14 | 2004-12-14 | |
| PCT/US2005/044116 WO2006065582A2 (en) | 2004-12-14 | 2005-12-07 | Muteins of fibroblast growth factor 21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008522617A JP2008522617A (ja) | 2008-07-03 |
| JP2008522617A5 true JP2008522617A5 (enExample) | 2009-01-15 |
Family
ID=36035700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545564A Withdrawn JP2008522617A (ja) | 2004-12-14 | 2005-12-07 | 線維芽細胞成長因子２１の突然変異タンパク質 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7655627B2 (enExample) |
| EP (1) | EP1831371A2 (enExample) |
| JP (1) | JP2008522617A (enExample) |
| WO (1) | WO2006065582A2 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| PL2068909T3 (pl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modyfikowane polipeptydy fgf-21 i ich zastosowanie |
| CA2687746A1 (en) * | 2007-05-22 | 2008-12-18 | Novartis Ag | Methods of treating, diagnosing and detecting fgf21-associated disorders |
| EA024751B8 (ru) * | 2008-06-04 | 2020-01-31 | Амген Инк. | Мутанты fgf21 и их применение |
| EP2358749B1 (en) * | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21 mutants and uses thereof |
| AU2013211503C1 (en) * | 2008-10-10 | 2016-09-29 | Amgen Inc. | FGF21 mutants and uses thereof |
| ES2692495T3 (es) | 2009-01-23 | 2018-12-03 | Novo Nordisk A/S | Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos |
| US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| SMT202400036T1 (it) * | 2009-05-05 | 2024-03-13 | Amgen Inc | Mutanti fgf21 e loro utilizzi |
| AU2010262927A1 (en) | 2009-06-17 | 2012-01-19 | Amgen Inc. | Chimeric FGF19 polypeptides and uses thereof |
| EP2493495A4 (en) * | 2009-07-10 | 2013-08-21 | Univ Northwestern | HERZSCHÜTZENDE ROLE OF LIVER CELLS AND SEKRETORIC FACTORS FROM LIVER CELLS IN MYOCARDIAN EMERGENCE |
| MX2012006397A (es) | 2009-12-02 | 2012-11-30 | Amgen Inc | PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA. |
| UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| EP2359843A1 (en) | 2010-01-21 | 2011-08-24 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| US9517264B2 (en) | 2010-04-15 | 2016-12-13 | Amgen Inc. | Human FGF receptor and β-Klotho binding proteins |
| CA2796459C (en) | 2010-04-16 | 2016-05-24 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf-1 |
| JP2013533227A (ja) | 2010-06-08 | 2013-08-22 | ノヴォ ノルディスク アー／エス | Ｆｇｆ２１類似体および誘導体 |
| CN103415300B (zh) | 2010-07-20 | 2018-02-23 | 诺沃—诺迪斯克有限公司 | N‑末端修饰的fgf21化合物 |
| BR112013011172A2 (pt) | 2010-11-05 | 2017-06-06 | Covx Tech Ireland Ltd | compostos antidiabéticos |
| US8754044B2 (en) | 2011-05-03 | 2014-06-17 | Northwestern University | Neuroprotection by hepatic cells and hepatocyte secretory factors |
| PE20140995A1 (es) | 2011-05-16 | 2014-08-23 | Genentech Inc | Agonistas de fgfr1 y sus metodos de uso |
| PL2726511T3 (pl) | 2011-07-01 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych |
| EP2548570A1 (en) | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| CA2859969A1 (en) | 2011-12-22 | 2013-06-27 | Pfizer Inc. | Processes for purifying a sample of h38c2 antibody or variant thereof |
| LT2814842T (lt) | 2012-02-15 | 2018-11-12 | Novo Nordisk A/S | Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1 |
| LT2814844T (lt) | 2012-02-15 | 2017-10-25 | Novo Nordisk A/S | Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1) |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| US9475856B2 (en) | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
| US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
| US9474785B2 (en) | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
| US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG11201504815QA (en) | 2012-12-27 | 2015-07-30 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2014130659A1 (en) | 2013-02-22 | 2014-08-28 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| CA2928135A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
| WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| NZ718962A (en) | 2013-10-28 | 2019-12-20 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
| AU2015209131B2 (en) | 2014-01-24 | 2020-06-25 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN106536559B (zh) | 2014-07-17 | 2021-04-27 | 诺和诺德股份有限公司 | 定点诱变trem-1抗体以降低黏度 |
| CN114129709A (zh) | 2014-10-23 | 2022-03-04 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| HUE044783T2 (hu) | 2014-12-23 | 2019-11-28 | Novo Nordisk As | FGF21 származékok és alkalmazásaik |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| AU2016344134A1 (en) | 2015-10-30 | 2018-05-31 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs |
| CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技（上海）有限公司 | 双特异性抗体及其制备方法与用途 |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN108570109B (zh) | 2017-03-14 | 2022-04-26 | 广东东阳光药业有限公司 | 包含免疫球蛋白Fc部分的双靶点融合蛋白 |
| CN111050786A (zh) | 2017-09-08 | 2020-04-21 | 百时美施贵宝公司 | 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21) |
| WO2019119673A1 (zh) | 2017-12-19 | 2019-06-27 | 北京吉源生物科技有限公司 | 一种双基因修饰的干细胞及其用途 |
| TWI790370B (zh) | 2018-04-02 | 2023-01-21 | 美商必治妥美雅史谷比公司 | 抗trem-1抗體及其用途 |
| US12226451B2 (en) | 2018-07-03 | 2025-02-18 | Bristol-Myers Squibb Company | FGF-21 formulations |
| JP2022506649A (ja) | 2018-11-05 | 2022-01-17 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｅｇ化タンパク質の精製方法 |
| US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
| WO2021142143A1 (en) | 2020-01-08 | 2021-07-15 | Bristol-Myers Squibb Company | Fgf-21 conjugate formulations |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| EP4192495A1 (en) | 2020-08-07 | 2023-06-14 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| WO2022115597A1 (en) | 2020-11-25 | 2022-06-02 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US6716626B1 (en) * | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| AU2003270424A1 (en) | 2002-09-09 | 2004-03-29 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| AU2004303783A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
-
2005
- 2005-12-07 US US11/718,636 patent/US7655627B2/en not_active Expired - Fee Related
- 2005-12-07 EP EP05853126A patent/EP1831371A2/en not_active Withdrawn
- 2005-12-07 JP JP2007545564A patent/JP2008522617A/ja not_active Withdrawn
- 2005-12-07 WO PCT/US2005/044116 patent/WO2006065582A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008522617A5 (enExample) | ||
| JP4809352B2 (ja) | 線維芽細胞成長因子２１の突然変異タンパク質 | |
| US7655627B2 (en) | Muteins of fibroblast growth factor 21 | |
| US7622445B2 (en) | Muteins of fibroblast growth factor 21 | |
| JP2008511323A5 (enExample) | ||
| JP6425674B2 (ja) | 凍結乾燥した組換え型ｖｗｆ製剤 | |
| JP2012506387A5 (enExample) | ||
| US20130052213A1 (en) | Novel immunomodulatory peptide | |
| KR100700869B1 (ko) | Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물 | |
| CN103827141B (zh) | 新型α-1抗胰蛋白酶变体及其制备方法和用途 | |
| WO2002081507A3 (en) | Interferon gamma polypeptide variants | |
| US20080200378A1 (en) | KGF polypeptide compositions | |
| CN1229138C (zh) | 加速粘液纤毛的清除速率的方法 | |
| JP2011501675A5 (enExample) | ||
| JPH1192499A (ja) | ヒト成長ホルモン変異体 | |
| US20110144002A1 (en) | Use of AMPs for Treatment of UTI/Cystitis | |
| HK1109408A (en) | Muteins of fibroblast growth factor 21 | |
| HK1150805A (en) | Recombinant vwf formulations |